Printer Friendly

Pharma Leader Series: Top Generic Drug Producers - Leading Companies and Forecasts 2015-2025.

LONDON, July 27, 2015 /PRNewswire/ --

Prospects for Development, Manufacturing and Business Expansion

Generic Drug Producers - Discover Top Companies' Revenue Prospects Now, Benefiting Your Influence

What does the future hold for manufacturers and sellers of generic medicines?Visiongain's new report shows you leading companies' prospects to 2025. That study lets you discover results, trends, opportunities and revenue forecasts, helping you stay ahead in knowledge.

For leading producers and marketers of generic drugs, you find information on established and rising companies. Explore their sales potentials in the generics market, seeing from 2015 to 2025 the prospects of industry leaders. What revenues are possible?

Sales predictions and other data to help you stay ahead in competitive intelligence

In our study you find analytical profiles of top generics producers. By region you analyse historical data, activities, revenue forecasts and growth rates. Discover qualitative analysis too. That work gives you 82 tables, 87 charts and two interviews with the industry.

Our new analysis shows you the most lucrative parts of the world industry for generic drugs. See today how you can benefit your research, analyses, decisions, proposals and presentations, also saving time and benefiting your reputation for insight.

Assessments of top companies - capabilities, results, competition and sales potentials

Our report assesses 43 leading manufacturers of generic medicines worldwide. In general a company profile gives you the following information:

* Discussion of activities, technologies and recent financial results

* Assessment of developments - mergers and acquisitions (M&A), new products, outlooks, challenges and plans

* Forecasting of generic drug revenues to 2025 (for 19 leading companies).

Discover capabilities, progress and prospects of top generics companies, grouped by region, helping you stay ahead in commercial knowledge and influence. Our study explains the changing generics industry from 2015 to 2025, including opportunities.

For the top 50 generic drug manufacturers in 2014, discover revenues and rankings. Also see top companies' gross profit margins, EBITDA margins and historical revenue growth.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

The following sections show how our new investigation helps your work.

North America - outlooks for leading generic drug producers and sellers

First our report analyses 13 North American generics specialists and big pharma companies in that market, including these firms:

* Mylan

* Pfizer

* Abbott

* Hospira

* Apotex

* Par Pharmaceuticals

In that analysis you find where revenue growth occurs and how high sales can go. Many opportunities remain, with high, expanding revenues possible from 2015.

Europe - prospects for leading generics players

Our survey also shows you outlooks for 10 European generics specialists and pharmaceutical leaders in that industry, including these firms:

* Novartis (Sandoz)

* Actavis

* Sanofi

* Fresenius Kabi

* Pharmstandard

* Gedeon Richter

* Stada Arzneimittel

The report shows you how companies can seize opportunities and expand their businesses from 2015 to 2025. You also examine organisations competing for shares of that expanding, evolving market.

India - analysis of leading generic drug firms

Our new work also assesses 10 Indian generic drug producers, including these firms:

* Sun Pharmaceutical Industries

* Dr. Reddy's Laboratories

* Lupin

* Ranbaxy

* Aurobindo

* Glenmark

* Wockhardt

How much sales growth and geographical expansion can Indian generics companies achieve from 2015? Our study shows you revenue data, trends and prospects, examining what opportunities and potentials exist.

Producers from the rest of world - assess technologies, progress and prospects

Our investigation also shows you outlooks for 10 generic drug makers based in other countries, including these companies:

* Teva Pharmaceutical Industries

* EMS

* Aspen Pharmacare

* Nichi-Iko

* Abdi Ibrahim

* Hypermarcas

* Eurofarma

* Sawai Pharmaceuticals

Countries such as Japan, Brazil and China will become increasingly important for generic drug development, production and sales from 2015 to 2025, our analyses show.

That work explains forces shaping the generics market and industry, helping you explore changes, challenges and opportunities. Discover what the future holds.

Issues affecting generic drug development, manufacturing and sales

Our report discusses issues and events affecting that industry and market from 2015, including these forces:

* Specialty generics - difficult-to-produce medicines with high profit margins

* Shift towards innovative and improved drugs, via expanding R&D budgets

* Mergers and acquisitions (M&A) influencing that expanding healthcare market

* Big pharma firms targeting generics - diversification of product portfolios

* International expansion - targeting developed and developing national markets

* Intellectual property - regulations, challenges and developments

* Biosimilars - opportunities for generic and originator drug companies

There you explore the generic drug industry's strengths, weaknesses, opportunities and threats. With our study you discover what the future holds for top generic drug producers.

You also gain our interviews with Sanofi Generics and the Generic Pharmaceutical Association (GPhA). Hear what participants think, say and do, helping you stay ahead.

Ways Top Generic Drug Producers - Leading Companies and Forecasts 2015-2025

- Prospects for Development, Manufacturing and Business Expansion helps

In particular, our new analysis benefits your work in these five main ways:

*Profiles of 43 generics companies - assess product ranges, strategies and sales results, also gaining revenue forecasts to 2025 for 19 organisations

*Competition and opportunities - explore what shapes the generic drugs market's future, especially companies' prospects for sustaining and expanding business

*Analysis of what benefits and restrains generic drug makers - assess challenges and strengths, helping you compete and gain advantages

*Reviews of established competitors and rising players in the generics sector - explore needs, competition, technologies and outlooks for future success

*Interviews with authorities - discover what participants in the industry think, say and do, helping you stay ahead in commercial knowledge.

That report, by visiongain's in-house analysts in the UK, gives information to benefit your work, saving you hassle and time. You gain data leading companies depend on.

Knowledge found nowhere else, helping your research, analyses and decisions

Our investigation gives independent analysis. You receive competitive intelligence found only in that report, discovering generics companies with the most commercial promise.

With our new survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions. Also find how you can save time and gain in recognition for insight, benefiting your authority.

Predictions for generic drug production and sales - gain by trying our study now

Our new analysis shows you data, trends, opportunities and sales forecasts for top producers and sellers of generic drugs. Avoid missing out - please get our report here now.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

Organisations Mentioned in the Report

Abbott

AbbVie

Abdi Ibrahim

Abrika Pharmaceuticals

Ache

Actavis

Active Pharma

Adcock Ingram

Advance Vision Research

Aegera

Afrexa Life Sciences

Agouron Pharmaceuticals

Akorn Pharmaceuticals

Akrikhin

Alcon

Allergan

Alpharma

Alvogen

AmerisourceBergen

Amide

Amneal Pharmaceuticals

AMS

APL Holdings Limited

ApoPharma

Apotex

Apotex Fermentation

APP Pharmaceuticals

Aprogen

Arrow Group

Asahi Kasei Pharma Corporation

Ascent Pharmahealth

ASKA Pharmaceutical

Aspen

Aspen Pharmacare

Aspen Trading

AstraZeneca

Auden McKenzie

Aurigene Discovery Technologies

Auro Pharma

Aurobindo

Balkanpharma

Barr Pharmaceuticals

Bausch and Lomb Holdings

Bayer

Bayer Yakuhin

BeiKang Pharmaceutical

Bever

Biocad Holding

Bioniche Pharma

Biovena

Boca Pharmacal

Boehringer Ingelheim

Brainfarma Industria e Farmaceutica

Bremer Pharma

Bunker and Delta

Cadila Healthcare

Cardinal Health

Cenova Pharma

CFR Pharmaceuticals

Chatted

Chattem Chemicals

Chimpharm

Chiron Corporation

Chirotech Technology

CIBA VISION

Cipla

CNS Therapeutics

Colotech

Cosmed Industria de Cosmeticos e Medicamentos S.A.

D. Searle & Company

Dabur Pharma

DACA Pharmaceuticals

Daichi Kasei

Dialfor Health

DKSH

Dr. Reddy's Laboratories

Dream Pharma

Dusa Pharmaceuticals

EBEWE Pharma

Elan Pharmaceuticals

Elder Pharmaceuticals

Emcure

Emergent Biosolutions

Emploi Quebec

European Medicines Agency

EMS

Endo

Eon Labs

Ethics Bio Lab

Eurofarma

Facet Biotech

Fako

Fenwal

Filaxis

Fougera Pharmaceuticals

Fresenius Kabi

Fuso Pharmaceutical Industries

Gangene Corp

Gedeon Richter

Generic Health

Generic Pharmaceutical Association (GPhA)

Genfar S.A.

Genzyme

Germa Pharm

GlaxoSmithKline (GSK)

Glenmark

Globalpharma

Golden Cross Pharma

Greenstone

Handok

HealthTronics

Helvepharm

Herbapol Pruszkow

Hexa

Hikma

Hi-Tech Pharmacal

Hospira

Hypermarcas

IDEV Technologies

Ikaria

Innopharma

Inspire Pharmaceuticals

Investissement Quebec

Ipca Laboratories

J-DOLPH Pharmaceutical

Johnson & Johnson

JPH Group Holdings

Kanghong Sagen Pharmaceuticals

Keri Pharma

Kilitch Drugs

Kolmar Holdings

Krka

Kunwha Pharmaceuticals

Kyowa Pharmaceuticals

Labesfal

Laboratorio Sanderson

Laboratorios Gautier

Laboratorios Grin

Laboratorios Kendrick

Labormed Pharma

Leek

Lekko

Les Laboratoires Servier SAS

Lotus Pharmaceuticals

Lupin

mAbxience

Madaus

Mallinckrodt

Maruko Pharmaceutical

Masterlek

McKesson Drug Company

Mechnikov Biomed

Mediate Specialities

Medina

Medisa Shinyaku

Medley Industria Farmaceutica

Meiji Seika Pharma

Merck & Co

Microdose

Mitani Sangyo

Mitsubishi Tanabe Pharma

MJ Pharma

Multicare

Mylan Laboratories

Nanomi B.V

National Druggists

NBZ Pharma Limited

Negma

Nichi-Iko

Nichi-Iko Pharma Tech

Nicox

Nippon Chemipher

Nippon Kayaku

NIXS Corporation

Novartis

Nycomed

Oak Pharmaceuticals

OctoPlus

Omega Laboratories Limited

Onset Dermatologics

Onyx

Oriel Therapeutics

Orion

Paladin Labs

Par Pharmaceutical

Parke-Davis

Pendopharm

Perrigo Company

Pfizer

PGT Healthcare

Pharma Avalanche

Pharmacin

Pharmapark

Pharmascience

Pharmascience Korea

PharmaSwiss

Pharmstandard

Pharmstandard Biotec

Phlox Pharma

Pinewood Laboratories

Piramal Healthcare Solutions

Polfa Warszawa

Polpharma

Pradeep Drug Company

Promius Pharma

Pymepharco

Qalitest

Questcor

Ranbaxy Laboratories

Ranbaxy Life Sciences Research

Ratiopharm

Ribbon

Richter-Helm

Roche

Romark Laboratories

Sabex

Sagent Acquisition Corp

Salix Pharmaceuticals

Sandoz

Sanofi

Sanofi Pasteur

Sawai Pharmaceuticals

Schein Pharmaceutical

Sekisui Medical

Shantha Biotechnics

Silom Medical Company

Sindan

Solus Pharmaceuticals

Solvay Pharmaceuticals

Somar

Specifar Pharmaceuticals S.A.

SPIL de Mexico

Spirig Pharma

Stada Arzneimittel

STARLIMS

Sun Pharmaceutical

Swisse Wellness

Taiyo Cephalon

Taro

Technologies Inc

Teikoku Medix

Terapia S.A.

Teva Pharmaceutical Industries

The European Generic Medicines Association (EGA)

The Generic Pharmaceutical Association

TKS Pharmaceutical

Torrent Pharmaceuticals

Towa

UDL Laboratories

United Research Laboratories

URL Pharma

US Food and Drug Administration (FDA)

Uteron Pharma S.A.

Valeant

Velefarm

Veropharm

VersaPharm Incorporated

Vindexpharm

VPI Holdings Corp

Warner Chilcott

Warner Lambert

Watson Pharmaceuticals

Winthrop

Wockhardt

Wyeth

Yakuhan Pharmaceuticals

ZAO Ranbaxy

Zao Sun Pharma

Zhejiang Chiral Medicine Chemicals Company

ZiO Zdorovje

Zoetis

Zydus Pharmaceuticals

Zydus Wellness

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com

or call Tel: +44(0)20-7336-6100

Or click on https://goo.gl/hmzcPM
COPYRIGHT 2015 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire Europe
Date:Jul 27, 2015
Words:2541
Previous Article:Metal Packaging Market Report 2015-2025: How Will Metal Packaging Compete Against Plastic Given Rising Environmental Concerns?
Next Article:Address Data-driven Marketing Challenges With LakeB2B at the B2B LeadsCon Summit.
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters